Antiphospholipid antibodies: A new risk factor for restenosis after percutaneous transluminal coronary angioplasty?

Autoimmunity

Volumn 27, Issue 3, 1998, Pages 141-148

  Ludia, Chiarugi ^a   Domenico, Prisco ^a   Monia, Capanni ^a   Emilia, Antonucci ^a   Sandra, Fedi ^a   Agatina, Alessandrello Liotta ^b   Massimo, Margheri ^b   Cristina, Giglioli ^b   Piero, Dabizzi Roberto ^a   Ignazio, Simonetti ^a   Rosanna, Abbate ^a   Franco, Gensini Gian ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

^b CAREGGI UNIVERSITY HOSPITAL   (Italy)

Author keywords

Anticardiolipin antibodies; Antiphospholipid antibodies; Lupus anticoagulant; Percutaneous transluminal coronary angioplasty; Restenosis

Indexed keywords

CARDIOLIPIN ANTIBODY; LUPUS ANTICOAGULANT; PHOSPHOLIPID ANTIBODY; PLASMINOGEN ACTIVATOR INHIBITOR; THROMBIN ANTITHROMBIN COMPLEX;

ADULT; AGED; ANGINA PECTORIS; ARTERY THROMBOSIS; ARTICLE; EXERCISE TEST; FEMALE; HEMOSTASIS; HUMAN; HYPERCOAGULABILITY; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; RESTENOSIS; RISK FACTOR; TRANSLUMINAL CORONARY ANGIOPLASTY; VEIN THROMBOSIS;

EID: 7144254464     PISSN: 08916934     EISSN: None     Source Type: Journal    
DOI: 10.3109/08916939809003861     Document Type: Article

References (39)

1. Brenner, B., Blumenfeld, Z., Markiewicz, W. and Reisner, S. A. (1991). Cardiac involvement in patients with primary antiphospholipid syndrome. J Am Coll Cardiol, 4, 931-936.
2. Lechner, K., Eichinger, S., Jager, U., Pabinger, I. and Kyrle, P. A. (1992). Lupus anticoagulant and clinical correlates. In: Neri Serneri, G.G. et al. (eds) Thrombosis: an update., Scientific Press, Florence, p. 47.
3. Nencini, P., Baruffi, M. C., Abbate, R., Massai, G., Amaducci, L. and Inzilari, D. (1992). Lupus anticoagulant and anticardiolipin antibodies in young adults with cerebral ischemia. Stroke, 23, 29-32.
4. Brandt, J. T., Triplett, D. A., Alving, B. and Sharrer, I. (1995). Criteria for diagnosis of lupus anticoagulant: an update. On behalf of the subcommittee on lupus anti-coagulant/antiphospholipid antibody of the Scientific and Standardization Committee of ISTH. Thromb Haemost, 74, 1185-1190.
5. Triplett, D. A. (1995). Antiphospholipid-protein antibodies: laboratory detection and clinical relevance. Thromb Res, 78, 1-31.
6. Libby, P., Schwartz, D., Brogi, E., Tanaka, H. and Clinton, S. K. (1992). A cascade model for restenosis. A special case of atherosclerosis progression. Circulation, 86, 47-52.
7. Savage, M. P., Goldberg, S., Bove, A. A., Deutsch, E., Vetrovec, G., Macdonald, R. G., Bass, T., Margolis, J. R., Withworth, H. B., Taussig, A., Hirshfeld, J. W., Cowley, M., Hill, J. A., Marks, R. G., Fishman, D. L., Handberg, E., Herrmann, H. and Pepine, J. P. (1995). Effect of Thromboxane A2 blockade on clinical outcome and restenosis after successful coronary angioplasty. Circulation, 92, 3200-3294.
8. Serruys, P. N., Herrman, J. P. R., Simon, R., Rutschi, W., Bode, C., Laarman, G. S., Vandijk, R., Vandenbos, A., Umans, V. A. W. M., Fox, K. A. A., Close, P. and Deckers, J. W. for the Helvetica Investigators. (1995). A comparison of Hirudin with heparin in the prevention of restenosis after coronary angioplasty. N Engl J Med, 333, 757-763.
9. Tcheng, J. E., Harrington, R. A., Kotthe-Marchant, M., Kleiman, M. S., Ellis, S. G., Kereiakes, D. S., Mick, M. J., Navetta, F. I., Smith, S. E., Worley, S. S., Miller, S. A., Joseph, D. M., Sigmon, K. M., Kitt, M. M., Du Mee, C. P., Cauff, R. M. and Topol, E. J. for the IMPACT investigators. (1995). Multicenter, randomized double-blind placebo-controlled trial of the platelet integrin glicoprotein IIb/IIIa blocker integrelin in elective coronary intervention. Circulation, 91, 2151-2157.
10. Huber, K., Jorg, M., Probst, P., Schuster, E., Lang, L., Kaindl, F. and Binder, B. R. (1992). A decrease in plasminogen activator inhibitor-1 activity after successful percutaneous transluminal coronary angioplasty is associated with a significantly reduced risk for coronary restenosis. Thromb Haemost, 67, 209-213.
11. Sakata, K., Miura, F., Sugino, H., Shinobe, M., Shirotani, M., Yoshida, H., Mori, N., Hoshino, T. and Takada, A. (1996). Impaired fibrinolysis early after percutaneous transluminal coronary angioplasty is associated with restenosis. Am Heart J, 131, 1-6.
12. Piette, J.-C. (1996). Diagnostic and classification criteria for the antiphospholipid/cofactors syndrome: a mission impossible? Lupus, 5, 354-363.
13. Dotter, C. T. and Judkins, M. P. (1964). Transluminal treatment of arteriosclerotic obstruction: description of a new technique and a preliminary report of its application. Circulation. 30, 654-10.
14. De Groote, P., Bauters, C., McFadden, E., Lablanche, J. M., Leroy, F. and Bertrand, M. E. (1995). Local lesion-related factors and restenosis after coronary angioplasty. Circulation, 91, 968-972.
15. Exner, T., Triplett, D. A., Taberner, D. and Machin, S. J. (1991). Guidelines for testing and revised criteria for lupus anticoagulant. SSC subcommittee for the standardization of lupus anticoagulant. Thromb Haemost, 65, 320-322.
16. Lupus anticoagulant working party of BCSH 1991. Haemostasis and thrombosis task force. Guidelines on testing for the lupus anticoagulant. J Clin Pathol, 44, 885-889.
17. Alving, B. M., Carr, C. F., Johansen, L. E. and Tang, D. B. (1992). Comparison between a onepoint dilute phospholipid aPTT and dilute Russel viper venom time for verification of lupus anticoagulants. Thromb Haemost, 62, 672-678.
18. O'Neil, A. L., Abrahaim, K. M. A. and Parkin, J. D. (1992). Automation of the caolin clotting time. Pathology, 24, 12-24.
19. Robert, A. (1994). Two different incubation times for activated partial thromboplastin time (aPTT): a new criterion for diagnosis of lupus anticoagulant. Thromb Haemost, 71, 220-224.
20. Triplett, D. A., Brandt, J. T. and Kozacor, D. (1983). Laboratory diagnosis of lupus inhibitor: a comparison of the tissue thromboplastin inhibition procedure with a new platelet neutralization procedure. Am J Clin Pathol, 79, 678-682.
21. Harris, E. N. (1990). Annotation: antiphospholipid antibodies. Br J Haematol, 74, 1-9.
22. Branch, D. W., Silver, R. M., Blackwell, J. L., Reading, J. C. and Scott, J. R. (1990). Outcome of treated pregnancies in women with antiphospholipid antibodies. Br J Haematol, 74, 1-9.
23. Boddi, M., Prisco, D., Fedi, S., Cellai, A. P., Alessandrello Liotta, A., Parretti, E., Mecacci, F., Mello, G. and Abbate, R. (1996). Anthiphospholipid antibodies and pregnancy disorders in women with insulin dependent diabetes. Thromb Res, 82, 207-216.
24. Pelzer, H., Schwartz, A. and Stuber, W. (1991). Determination of human prothrombin activation fragment 1 + 2 in plasma with antibodies against a synthetic peptide. Thromb Haemost, 65, 153-159.
25. Pelzer, H., Schwartz, A. and Heimberg, N. (1988). Determination of human thrombin-antithrombin complex in plasma with an enzyme linked immuno-sorbent assay. Thromb Haemost, 59, 101-106.
26. Elms, M. J., Bunce, I. H., Bundesen, P. G., Rylatt, D. B., Webber, A. J., Masci, P. P. and Whitaker, A. N. (1983). Measurement of cross-linked fibrin degradation products. An immuno-assay using monoclonal antibodies. Thromb Haemost, 50, 591-597.
27. Chmielewska, J., Ranby, H. and Wiman, D. (1983). Evidence for a rapid inhibitor to tissue plasminogen activator in plasma. Thromb Res, 31, 427-436.
28. Vaarala, O., Manttari, M., Manninen, V., Tenkanen, L., Puurunen, M., Aho, K. and Palosuo, T. (1994). Anti-cardiolipin antibodies and risk of myocardial infarction in a prospective cohort of middle aged men. Circulation, 91, 23-27.
29. Zukerman, E., Toubi, E., Shiran, A., Sabo, E., Shmuel, Z., Dov Golan, T., Abinader, E. and Yeshurun, D. (1996). Anticardiolipin antibodies and acute myocardial infarction in nonsystemic lupus erythematosus patients: a controlled prospective study. Am J Med, 171, 381-386.
30. Hamsten, A., Norberg, R., Bjorkholm, M., De Faire, U. and Holm, G. (1986). Antibodies to cardiolipin in young survivors of myocardial infarction: an association with recurrent cardiovascular events. Lancet, 1, 113-116.
31. Klemp, P., Cooper, R. C., Strauss, F. J., Jordan, E. R., Przybojewski, J. Z. and Nel, N. (1988). Anticardiolipin antibodies in ischaemic heart disease. Clin Exp Immunol., 74, 254-257.
32. Hendra, T. J., Baguley, E. and Harris, E. N. (1989). Anticardiolipin antibodies levels in diabetic subjects with and without coronary artery disease. Postgrad Med J, 65, 140-3.
33. The antiphospholipid antibodies in stroke study group (APASS). 1990, Clinical and laboratory findings in patients with antiphospholipid antibodies and cerebral ischemia Stroke, 21, 1268-1273.
34. Neri Serneri, G. G., Abbate, R., Gori, A. M., Attanasio, M., Martini, F., Giusti, B., Dabizzi, R. P., Poggesi, L., Modesti, P. A., Trotta, F., Rostagno, C., Boddi, M. and Gensini, G. F. (1992). Transient intermittent lymphocyte activation is responsible for the instability of angina. Circulation, 86, 790-797.
35. Liuzzo, G., Biasucci, L. M., Gallimore, J. R., Grillo, R. I., Rebuzzi, A. G., Pepys, S. M. B. and Maseri, A. (1994). The prognostic value of C-reactive protein and serum amyloid A protein in severe unstable angina. N Engl J Med, 33, 414-424.
36. Neri Semeri, G. G., Prisco, D., Martini, F., Gori, A. M., Brunelli, T., Poggesi, L., Rostagno, C., Gensini, G. F. and Abbate, R. (1997). An acute T cell activation is detectable in unstable angina. Circulation, 95, 1806-1812.
37. Bittl, J. A. (1996). Advances in coronary angioplasty. N Engl J Med, 335, 1290-1302.
38. Eber, B., Schumaker, M., Auer-Grumbach, P., Toplac, H. and Klein, W. (1992). Increased IgM-anticardiolipin antibodies in patients with restenosis after percutaneous transluminal coronary angioplasty. Am J Cardiol, 69, 1255-1258.
39. Morton, K. E., Krilis, A. S., Baron, D. W., Gavaghan, T. P., Daggard, G. E., Hickie, J. B. and Chesterman, C. N. (1986). Coronary artery By-Pass graft failure - an autoimmune phenomenon? Lancet, 2, 1353-1358.